{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/follistatin-344\/","title":{"rendered":"Follistatina 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es la Follistatina 344?<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatina 344<\/strong> (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin\/myostatin signalling axis. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6 (follistatina)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glicoprote\u00edna recombinante (isoforma de empalme FST-344 de 344 amino\u00e1cidos de la follistatina humana)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~37 kDa (forma glicosilada madura; rango observado de ~38\u201342 kDa en SDS-PAGE seg\u00fan el estado de glicosilaci\u00f3n)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estructura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dominio de uni\u00f3n a heparina en el extremo N-terminal seguido de tres dominios de follistatina (FSD1, FSD2, FSD3), cada uno con un subdominio tipo EGF y otro tipo Kazal; rico en ciste\u00ednas, con m\u00faltiples puentes disulfuro intramoleculares<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante liofilizada (de color blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595% (verificado por HPLC, COA disponible bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar en ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida \u2014 las prote\u00ednas recombinantes son especialmente sensibles a la desnaturalizaci\u00f3n por congelaci\u00f3n-descongelaci\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para per\u00edodos de uso m\u00e1s cortos. Prote\u00edna transportadora (BSA, 0,1%) opcional para diluciones de trabajo para minimizar p\u00e9rdidas por adsorci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la Follistatina 344?<\/h2>\n<p><strong>Follistatina 344<\/strong> (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin \u2014 the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role \u2014 high-affinity binding and neutralisation of activin and myostatin \u2014 was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37\u00a0kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42\u00a0kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> p\u00e1gina de producto. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Antagonismo de las v\u00edas de la miostatina y la activina<\/h2>\n<p>What makes follistatin 344 mechanistically unique among muscle-studies proteins is its <strong>perfil de uni\u00f3n multiobjetivo<\/strong> across the TGF-\u03b2 superfamily \u2014 each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:<\/p>\n<ul>\n<li><strong>Secuestro de miostatina (GDF-8) \u2014 eje de hipertrofia muscular<\/strong> \u2014 Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the &#8220;double-muscling&#8221; phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.<\/li>\n<li><strong>Secuestro de activina A y B \u2014 se\u00f1alizaci\u00f3n reproductiva, ov\u00e1rica y pituitaria<\/strong> \u2014 Follistatin&#8217;s original characterised function was binding and neutralising activin, a related TGF-\u03b2 superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin\/inhibin balance in study models and modulates downstream Smad2\/Smad3 signalling.<\/li>\n<li><strong>Modulaci\u00f3n de GDF-11 y la superfamilia TGF-\u03b2 en general<\/strong> \u2014 Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-\u03b2 superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.<\/li>\n<\/ul>\n<p>The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants \u2014 FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Follistatin 344 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle hypertrophy and protein synthesis studies<\/strong> \u2014 modelos de hipertrofia en ratones y ratas, incluyendo estudios de administraci\u00f3n g\u00e9nica con AAV-follistatina (Kota et al., Sci Transl Med 2009); \u00e1rea transversal espec\u00edfica del tipo de fibra, peso h\u00famedo muscular, generaci\u00f3n de fuerza<\/li>\n<li><strong>Modelos precl\u00ednicos de distrofia muscular<\/strong> \u2014 modelo de rat\u00f3n mdx para distrofia muscular de Duchenne; capacidad funcional, regeneraci\u00f3n de fibras, preservaci\u00f3n muscular independiente de distrofina<\/li>\n<li><strong>Investigaci\u00f3n sobre sarcopenia y p\u00e9rdida muscular relacionada con la edad<\/strong> \u2014 aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies<\/li>\n<li><strong>Cancer cachexia studies<\/strong> \u2014 modelos de caquexia en ratones con tumores, preservaci\u00f3n de la composici\u00f3n corporal, relaci\u00f3n masa magra\/masa grasa<\/li>\n<li><strong>Reproductive endocrinology studies<\/strong> \u2014 FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies<\/li>\n<li><strong>Activin pathway studies<\/strong> \u2014 Smad2\/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration<\/li>\n<li><strong>Aging and GDF-11 axis studies<\/strong> \u2014 cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11\/myostatin balance with aging<\/li>\n<li><strong>Comparative anabolic studies<\/strong> \u2014 frente a frente con <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.<\/li>\n<\/ul>\n<p>For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> como comparador can\u00f3nico del eje IGF, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for GHRH-axis growth studies, and <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 muscle hypertrophy and activin\/myostatin axis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 is a 37\u00a0kDa recombinant glycoprotein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format is the standard strength for in vivo and in vitro work \u2014 one vial reconstituted with 1.0\u00a0mL bacteriostatic water yields a 1\u00a0mg\/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections. <\/p>\n<h2>Comparativa \u2014 Follistatina 344 vs IGF-1 LR3<\/h2>\n<p>La Follistatina 344 y <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways \u2014 follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt\/mTOR protein synthesis \u2014 which makes them mechanistically complementary in protocols. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatina 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344 amino\u00e1cidos (glicoprote\u00edna recombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83 amino\u00e1cidos (IGF-1 modificado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Secuestro de miostatina\/activina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo del receptor IGF-1 \u2192 Akt\/mTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modo de efecto<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Desinhibici\u00f3n (elimina el freno del crecimiento)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estimulaci\u00f3n anab\u00f3lica directa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100\u00a0mcg, 1\u20133 veces por semana<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\u201360\u00a0mcg, diariamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hipertrofia muscular completa, modelos de distrofia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Local hypertrophy, regenerative anabolic studies<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with IGF-1 LR3 in hypertrophy studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Com\u00fanmente coadministrado con follistatina 344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Because the two proteins act on fundamentally different anabolic axes \u2014 follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis \u2014 combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF\/Akt\/mTOR anabolic studies, IGF-1 LR3 is the canonical tool. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> Almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su embalaje original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. La follistatina 344 liofilizada es estable bajo refrigeraci\u00f3n hasta 12 meses y a \u221220 \u00b0C hasta 24 meses \u2014 un per\u00edodo ligeramente m\u00e1s corto que el de los p\u00e9ptidos sint\u00e9ticos peque\u00f1os debido a que la glicoprote\u00edna recombinante m\u00e1s grande es m\u00e1s susceptible a desamidaci\u00f3n y oxidaci\u00f3n con el tiempo. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> Inyecte agua bacteriost\u00e1tica por la pared lateral del vial de p\u00e9ptidos (no directamente sobre el polvo liofilizado). Para un vial de 1 mg, 1.0 mL de agua bacteriost\u00e1tica produce una concentraci\u00f3n de trabajo de 1 mg\/mL. Agite suavemente \u2014 no sacuda \u2014 y permita 5\u201310 minutos para una disoluci\u00f3n completa. Las prote\u00ednas recombinantes se disuelven m\u00e1s lentamente que los p\u00e9ptidos peque\u00f1os; no apresure el paso de disoluci\u00f3n. Una soluci\u00f3n correctamente reconstituida debe ser clara e incolora sin part\u00edculas visibles. Para diluciones de trabajo por debajo de 100 mcg\/mL, la adici\u00f3n de prote\u00edna transportadora (BSA al 0.1% de concentraci\u00f3n final) minimiza las p\u00e9rdidas por adsorci\u00f3n en pl\u00e1stico y vidrio. <strong>ajuste<\/strong> Almacene refrigerado a 2\u20138 \u00b0C y utilice dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida \u2014 las glicoprote\u00ednas recombinantes son particularmente sensibles a la desnaturalizaci\u00f3n por congelaci\u00f3n-descongelaci\u00f3n, lo que produce agregaci\u00f3n y p\u00e9rdida de actividad. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> \u00bfPara qu\u00e9 se utiliza la Follistatina 344 en investigaci\u00f3n?. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Follistatin 344 used for in studies?<\/h3>\n<p>Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin\/myostatin\/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>FST-344 es el producto g\u00e9nico de la isoforma de 344 amino\u00e1cidos que incluye el p\u00e9ptido se\u00f1al; FST-315 es la misma prote\u00edna despu\u00e9s del corte del p\u00e9ptido se\u00f1al durante la secreci\u00f3n (por lo que FST-315 es la forma circulante madura de FST-344). Ambos sistemas de nomenclatura aparecen en la literatura y se refieren a la misma isoforma biol\u00f3gica. Ambos difieren sustancialmente de FST-288, que es una isoforma m\u00e1s corta con empalme alternativo con mayor uni\u00f3n a hepar\u00e1n sulfato y localizaci\u00f3n mayoritariamente en membrana.<\/h3>\n<p>\u00bfEn qu\u00e9 se diferencia la Follistatina 344 del IGF-1 LR3?. <\/p>\n<h3>Ambas son prote\u00ednas anab\u00f3licas recombinantes utilizadas en investigaci\u00f3n de hipertrofia muscular, pero act\u00faan sobre v\u00edas diferentes. La Follistatina 344 es una glicoprote\u00edna de 344 amino\u00e1cidos que une y secuestra miostatina y activina \u2014 funciona eliminando el freno end\u00f3geno del crecimiento muscular. El IGF-1 LR3 es un an\u00e1logo modificado de IGF-1 de 83 amino\u00e1cidos que agoniza directamente el receptor de IGF-1 y activa la s\u00edntesis proteica Akt\/mTOR. Ambas son complementarias mec\u00e1nicamente y frecuentemente se coadministran en investigaci\u00f3n.<\/h3>\n<p>Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin \u2014 it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt\/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies. <\/p>\n<h3>What is the typical Follistatin 344 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013100\u00a0mcg per administration in rodent models, given 1\u20133 times weekly for 4\u201312 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1\u00a0mg vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 0.01\u00a0mL equals 10\u00a0mcg, 0.1\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>\u00bfEst\u00e1 la Folistatina 344 aprobada por la FDA?<\/h3>\n<p>No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar la Folistatina 344?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o a \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congelar la soluci\u00f3n reconstituida \u2014 las glicoprote\u00ednas recombinantes son particularmente sensibles a la desnaturalizaci\u00f3n por congelaci\u00f3n-descongelaci\u00f3n. Proteger siempre de la luz directa. Se recomienda prote\u00edna transportadora (BSA al 0,1%) para diluciones de trabajo por debajo de 100 mcg\/mL. <\/p>\n<h3>\u00bfC\u00f3mo se reconstituye la Folistatina 344?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y deje reposar 5\u201310 minutos para una disoluci\u00f3n completa. No agite el vial \u2014 la agitaci\u00f3n vigorosa puede desnaturalizar prote\u00ednas recombinantes y causar agregaci\u00f3n. Una soluci\u00f3n correctamente reconstituida es clara e incolora. Para un vial de 1 mg + 1,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 1 mg\/mL. <strong>ajuste<\/strong> \u00bfPor qu\u00e9 la especificaci\u00f3n de pureza es del 95% y no del 99%?. <\/p>\n<h3>Las glicoprote\u00ednas recombinantes como la folistatina 344 no pueden alcanzar el est\u00e1ndar de pureza \u226599% en HPLC t\u00edpico de los p\u00e9ptidos sint\u00e9ticos peque\u00f1os debido a la heterogeneidad inherente de la glicosilaci\u00f3n en cualquier sistema de expresi\u00f3n recombinante \u2014 las diferentes formas de glicosilaci\u00f3n aparecen como picos relacionados en HPLC que no son impurezas sino isoformas de la prote\u00edna objetivo. Una pureza \u226595% en HPLC es la especificaci\u00f3n est\u00e1ndar de grado de investigaci\u00f3n para la folistatina 344 y glicoprote\u00ednas recombinantes similares. El SDS-PAGE suele mostrar una sola banda con el rango de masa aparente esperado de 38\u201342 kDa.<\/h3>\n<p>Recombinant glycoproteins like follistatin 344 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system \u2014 different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38\u201342\u00a0kDa apparent mass range. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Follistatin 344 and IGF-1 LR3 be stacked in studies?<\/h3>\n<p>Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area. <\/p>\n<h3>Does Follistatin 344 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin&#8217;s role in broader TGF-\u03b2 superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de la Follistatina 344?<\/h3>\n<p>In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1\u20133 hours following intravenous administration, reflecting its size (37\u00a0kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months. <\/p>\n<h3>How long does Follistatin 344 take to show effects in preclinical studies?<\/h3>\n<p>Los efectos de hipertrofia muscular en protocolos de inyecci\u00f3n de prote\u00ednas en ratones y ratas suelen ser estad\u00edsticamente significativos despu\u00e9s de 2 a 4 semanas de dosificaci\u00f3n semanal y contin\u00faan acumul\u00e1ndose hasta las 8-12 semanas. Los efectos sobre el eje activina\/FSH en par\u00e1metros reproductivos pueden detectarse a los pocos d\u00edas de la administraci\u00f3n. Los protocolos de administraci\u00f3n g\u00e9nica (AAV-follistatina) muestran hipertrofia muscular medible a las 4-6 semanas posteriores a la inyecci\u00f3n y contin\u00faan desarroll\u00e1ndose durante meses. <\/p>\n<h3>\u00bfPuedo pedir Follistatina 344 para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Follistatina 344 a todo el mundo desde nuestra red dedicada de env\u00edo de p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo de p\u00e9ptidos independiente. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Growth-Axis, and Muscle Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 direct IGF-1R agonist for Akt\/mTOR studies<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/es\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Agonista selectivo de grelina \u2014 pulso de GH limpio sin cortisol\/prolactina<\/li>\n<li><a href=\"\/es\/tb-500\/\"><strong>TB-500 (Timosina Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore anabolic and growth-axis peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados que incluyen <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Glicoprote\u00edna recombinante de 344 aa<br \/>\n\u2705 Antagonista de la v\u00eda de la miostatina y la activina<br \/>\n\u2705 Muscle hypertrophy compound<br \/>\n\u2705 Modelos precl\u00ednicos de distrofia muscular<br \/>\n\u2705 Pureza \u226595% por HPLC, COA disponible bajo solicitud<\/p>\n<p><strong>Follistatina 344<\/strong> es una prote\u00edna recombinante.<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":["post-70719","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-follistatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}